Clinical Trials
Gynecologic (GYN) Cancer
Endometrial
BMS CA 163196
A Phase III Open Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days VS Paclitaxel or Doxorubicin Administered Every 21 Days in Women with Advanced Endometrial Cancer Who Have Previously Been Treated with Chemotherapy.
- Principal Investigator: Patricia S. Braly, M.D.
Ovarian Carcinoma
Randomized, Double-Blind, Placebo Controlled A, Multi-Center, Phase II Study of Adding AMG 479, a fully Human Monoclonal Antibody against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients with Optimally Debulked (<1 cm) Epithelial Ovarian Cancer.
- Principal Investigator: Patricia S. Braly, M.D.
BIPI Protocol 1199.15: Multicenter, Randomized, Double-Blind Phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer.
- Principal Investigator: Patricia S. Braly, M.D.
Morab 003-004
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum-sensitive Ovarian Cancer in First Relapse.
- Principal Investigator: Patricia S. Braly, M.D.
Morab 003-003-PR A Randomized, Double-blind, Placebo-Controlled, Study of the Efficacy and Safety of MORAb-003 *(farletuzumab) in Combination with Paclitaxel Therapy in Subjects with Platinum-Resistant or Refractory Relapsed Ovarian Cancer.
- Principal Investigator: Patricia S. Braly, M.D.
Protocol 20090508: A Phase 3, Randomized, Double-blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women with Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers.
- Principal Investigator: Patricia S. Braly, M.D.
